New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
150-Loop
430-Loop
Host cell selection
Neuraminidase inhibitors
Receptor-binding
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
17
07
2023
revised:
07
09
2023
accepted:
14
09
2023
medline:
29
9
2023
pubmed:
18
9
2023
entrez:
17
9
2023
Statut:
ppublish
Résumé
Influenza virus neuraminidase (NA) can act as a receptor-binding protein, a role commonly attributed to hemagglutinin (HA). In influenza A(H3N2) viruses, three NA amino acid residues have previously been associated with NA-mediated hemagglutination: T148, D151, and more recently, H150. These residues are part of the 150-loop of the NA monomer. Substitutions at 148 and 151 arise from virus propagation in laboratory cell cultures, whereas changes at 150 occurred during virus evolution in the human host. In this study, we examined the effect of natural amino acid polymorphism at position 150 on NA-mediated hemagglutination. Using the A/Puerto Rico/8/34 backbone, we generated a comprehensive panel of recombinant A(H3N2) viruses that have different NAs but shared an HA that displays poor binding to red blood cells (RBCs). None of the tested substitutions at 150 (C, H, L, R, and S) promoted NA-binding. However, we identified two new determinants of NA-binding, Q136K and T439R, that emerged during virus culturing. Similar to T148I, both Q136K and T439R reduced NA enzyme activity by 48-86% and inhibition (14- to 173-fold) by the NA inhibitor zanamivir. NA-binding was observed when a virus preparation contained approximately 10% of NA variants with either T148I or T439R, highlighting the benefit of using deep sequencing in virus characterization. Taken together, our findings provide new insights into the molecular mechanisms underlying the ability of NA to function as a binding protein. Information gained may aid in the design of new and improved NA-targeting antivirals.
Identifiants
pubmed: 37717821
pii: S0166-3542(23)00197-3
doi: 10.1016/j.antiviral.2023.105719
pmc: PMC10549826
mid: NIHMS1932121
pii:
doi:
Substances chimiques
Amino Acids
0
Antiviral Agents
0
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
105719Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Gen Virol. 2020 May;101(5):456-466
pubmed: 31702542
Sci Rep. 2013;3:1551
pubmed: 23531861
Nat Rev Genet. 2007 Mar;8(3):196-205
pubmed: 17262054
Nature. 1983 May 5-11;303(5912):41-4
pubmed: 6188957
J Virol. 2013 Dec;87(23):12531-40
pubmed: 24027333
Nat Commun. 2022 Nov 3;13(1):6602
pubmed: 36329075
J Am Chem Soc. 2007 Jun 27;129(25):7764-5
pubmed: 17539643
Cell Host Microbe. 2017 Jan 11;21(1):23-34
pubmed: 28017661
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
pubmed: 10801978
Antiviral Res. 2010 Feb;85(2):381-8
pubmed: 19917319
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21474-9
pubmed: 23236176
J Gen Virol. 2017 Jun;98(6):1274-1281
pubmed: 28612701
J Infect Dis. 2019 Jul 31;220(5):820-829
pubmed: 31053844
BMC Genomics. 2016 Sep 05;17:708
pubmed: 27595578
Virology. 2015 Mar;477:18-31
pubmed: 25617824
Am J Public Health. 1997 Dec;87(12):1944-50
pubmed: 9431281
Influenza Other Respir Viruses. 2014 Mar;8(2):258-65
pubmed: 24299049
J Immunol. 2019 Jan 15;202(2):392-398
pubmed: 30617121
Respirology. 2003 Jun;8(2):231-3
pubmed: 12753540
Antiviral Res. 2023 Feb;210:105499
pubmed: 36567025
Antimicrob Agents Chemother. 2003 Jul;47(7):2264-72
pubmed: 12821478
Antiviral Res. 2014 Jan;101:93-6
pubmed: 24239666
J Virol. 2015 Jun;89(11):5935-48
pubmed: 25810540
Nature. 2006 Sep 7;443(7107):45-9
pubmed: 16915235
Sci Rep. 2019 Feb 25;9(1):2676
pubmed: 30804469
Elife. 2016 Mar 15;5:e13974
pubmed: 26978794
Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6
pubmed: 24080660
PLoS One. 2013 Jun 21;8(6):e66325
pubmed: 23805213
Antiviral Res. 2022 Apr;200:105280
pubmed: 35304163
Virology. 2000 Dec 20;278(2):587-96
pubmed: 11118381
Nat Microbiol. 2019 Aug;4(8):1268-1273
pubmed: 31036910
Nat Prod Rep. 2012 Jan;29(1):11-36
pubmed: 22025274
J Virol. 2012 Dec;86(24):13371-83
pubmed: 23015718
Virol J. 2015 Apr 22;12:67
pubmed: 25896455
J Clin Microbiol. 2008 Jul;46(7):2189-94
pubmed: 18480230
Euro Surveill. 2015;20(45):
pubmed: 26608955
Viruses. 2010 Oct;2(10):2269-2289
pubmed: 21994620
Emerg Infect Dis. 2010 Mar;16(3):493-6
pubmed: 20202427
J Clin Microbiol. 2011 Apr;49(4):1307-12
pubmed: 21307217
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18903-8
pubmed: 23012478
Antiviral Res. 2016 Aug;132:178-85
pubmed: 27265623
J Virol. 2010 Jul;84(13):6769-81
pubmed: 20410266